What are the potential side effects of spravato?

What side effects are most commonly reported with Spravato?

Spravato (esketamine) is given as a nasal spray under medical supervision, so most side effects occur during or shortly after the treatment session. The most frequent effects include dizziness, drowsiness, and a sense of disconnection from surroundings. Patients may also feel nauseous or experience a temporary rise in blood pressure. These reactions usually peak within the first hour and fade before the patient leaves the clinic.

How long do Spravato side effects typically last?

Most side effects resolve within two hours of dosing. Dizziness and sedation can linger for a few hours, so clinics require patients to stay for observation and arrange a ride home. Blood-pressure increases generally return to baseline within four hours. Lingering effects the next day are uncommon but can include mild fatigue or headache.

Can Spravato cause serious psychiatric reactions?

Because Spravato acts on NMDA receptors, it can trigger dissociative or hallucinatory experiences during the session. In rare cases these experiences intensify into anxiety, paranoia, or agitation. Clinics screen patients for a history of psychosis or unstable psychiatric illness precisely because these reactions carry higher risk in that group. Any severe reaction requires immediate medical attention and may lead to stopping treatment.

Does Spravato affect blood pressure long term?

Blood-pressure spikes are almost always limited to the hours after dosing. Sustained hypertension has not been observed in clinical studies, but patients with uncontrolled high blood pressure are usually excluded from treatment. Regular monitoring during sessions helps catch any outlier readings early.

How does Spravato compare with traditional antidepressants in terms of side effects?

Spravato’s side-effect profile centers on acute, session-related reactions rather than the daily gastrointestinal or sexual side effects seen with SSRIs. Weight gain and sexual dysfunction are rare. The trade-off is the need for in-clinic administration and the short-term dissociative effects that oral antidepressants do not produce.

Are there any long-term safety concerns with repeated Spravato use?

Data beyond one year are still limited. Animal studies raised theoretical concerns about bladder irritation with chronic ketamine use, but this effect has not been clearly linked to Spravato at approved doses. Ongoing registries track cognitive function and urinary symptoms in patients receiving long-term treatment.

Who should avoid Spravato because of side-effect risks?

Patients with a history of aneurysmal vascular disease, uncontrolled hypertension, or recent heart attack or stroke are generally advised against treatment. Pregnancy and breastfeeding are also contraindications because fetal safety data are lacking. Individuals with active substance-use disorders require careful evaluation because of ketamine’s abuse potential.

How is Spravato’s safety monitored in real-world use?

Prescribers must complete a Risk Evaluation and Mitigation Strategy (REMS) program. Each dose is logged, blood pressure is checked before and after, and patients cannot drive for the rest of the day. The REMS system collects adverse-event reports that feed into ongoing safety reviews.